[S02DA03, antipyrine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Etacrynic acid.]
[J01GA01, streptomycin, The serum concentration of Streptomycin can be increased when it is combined with Etacrynic acid.]
[M03AB01, succinylcholine, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Etacrynic acid.]
[A02BX02, sucralfate, Etacrynic acid may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Etacrynic acid may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Etacrynic acid.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Etacrynic acid.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Etacrynic acid.]
[M01AB02, sulindac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sulindac.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Etacrynic acid.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Etacrynic acid.]
[M01AX04, apazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Azapropazone.]
[N05CD07, temazepam, Etacrynic acid may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC03, terbutaline, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Etacrynic acid.]
[B01AE07, dabigatran etexilate, Etacrynic acid may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BA03, testosterone, Etacrynic acid may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA02, tetracycline, Etacrynic acid may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Ceftaroline fosamil.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Etacrynic acid.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Thalidomide.]
[P02CA02, thiabendazole, Etacrynic acid may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, Etacrynic acid may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Etacrynic acid.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Etacrynic acid.]
[G04BE06, moxisylyte, Etacrynic acid may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Etacrynic acid may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC05, ticlopidine, Etacrynic acid may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, Etacrynic acid may increase the excretion rate of Timolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01AB02, tinidazole, Etacrynic acid may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA12, tobramycin, The serum concentration of Tobramycin can be increased when it is combined with Etacrynic acid.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Etacrynic acid.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Tolazoline is combined with Etacrynic acid.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Etacrynic acid.]
[M02AA21, tolmetin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tolmetin.]
[N02AX02, tramadol, Etacrynic acid may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Etacrynic acid.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Etacrynic acid.]
[S01BA05, triamcinolone, The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Etacrynic acid.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Etacrynic acid.]
[N05CD05, triazolam, Etacrynic acid may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA06, trichlormethiazide, Etacrynic acid may increase the hypotensive activities of Trichlormethiazide.]
[A16AX12, trientine, Etacrynic acid may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AD02, trifluridine, Etacrynic acid may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC02, fluclorolone, The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Etacrynic acid.]
[A03AA05, trimebutine, Etacrynic acid may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Trimethaphan.]
[J01EA01, trimethoprim, Etacrynic acid may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, The therapeutic efficacy of Tubocurarine can be increased when used in combination with Etacrynic acid.]
[R03DX07, roflumilast, Etacrynic acid may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX04, ipilimumab, Etacrynic acid may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AA14, oxyquinoline, Etacrynic acid may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etacrynic acid.]
[S01AA28, vancomycin, Etacrynic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Etacrynic acid may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF01, rivaroxaban, Etacrynic acid may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC18, indacaterol, The risk or severity of hypokalemia can be increased when Indacaterol is combined with Etacrynic acid.]
[C08DA01, verapamil, Etacrynic acid may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX09, viloxazine, Etacrynic acid may increase the excretion rate of Viloxazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX07, vincamine, Etacrynic acid may increase the hypotensive activities of Vincamine.]
[B03BA01, vitamin B12, Etacrynic acid may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA03, warfarin, The protein binding of Warfarin can be decreased when combined with Etacrynic acid.]
[C03BA10, xipamide, Etacrynic acid may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The excretion of Zidovudine can be decreased when combined with Etacrynic acid.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Etacrynic acid.]
[M05BA05, tiludronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Tiludronic acid.]
[B06AC02, icatibant, Etacrynic acid may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC04, rabeprazole, Etacrynic acid may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA06, ibandronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Ibandronate.]
[V03AC02, deferiprone, Etacrynic acid may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Etacrynic acid which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Etacrynic acid may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD07, tolterodine, Etacrynic acid may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH04, doripenem, Etacrynic acid may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Atenolol is combined with Etacrynic acid.]
[M03AC04, atracurium, The therapeutic efficacy of Atracurium can be increased when used in combination with Etacrynic acid.]
[M01CB03, auranofin, Etacrynic acid may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB11, prednylidene, The risk or severity of hypokalemia can be increased when Prednylidene is combined with Etacrynic acid.]
[B03XA04, peginesatide, Etacrynic acid may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Etacrynic acid may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Etacrynic acid may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, Etacrynic acid may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DF01, aztreonam, Etacrynic acid may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Etacrynic acid.]
[G04BE10, avanafil, The risk or severity of hypotension can be increased when Avanafil is combined with Etacrynic acid.]
[M03BX01, baclofen, Etacrynic acid may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[A08AA11, lorcaserin, Etacrynic acid may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD12, mirabegron, Etacrynic acid may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BB04, enzalutamide, Etacrynic acid may increase the excretion rate of Enzalutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Linaclotide.]
[A02AA05, magnesium silicate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium silicate.]
[H02AA01, aldosterone, The risk or severity of hypokalemia can be increased when Aldosterone is combined with Etacrynic acid.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Etacrynic acid.]
[C01AA01, acetyldigitoxin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigitoxin.]
[D02BA02, octinoxate, Etacrynic acid may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Etacrynic acid.]
[C08CA13, lercanidipine, The risk or severity of adverse effects can be increased when Lercanidipine is combined with Etacrynic acid.]
[V09IX04, fluorodeoxyglucose F18, Etacrynic acid may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE03, sildenafil, The risk or severity of hypotension can be increased when Sildenafil is combined with Etacrynic acid.]
[V08CA11, gadofosveset, Etacrynic acid may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX08, teduglutide, Etacrynic acid may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Etacrynic acid.]
[A16AX09, glycerol phenylbutyrate, Etacrynic acid may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Etacrynic acid.]
[L04AX06, pomalidomide, Etacrynic acid may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA10, benorilate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of hypotension can be increased when Canagliflozin is combined with Etacrynic acid.]
[A12CC09, magnesium orotate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium orotate.]
[A06AX06, tegaserod, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tegaserod.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Etacrynic acid.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Etacrynic acid.]
[L03AA12, ancestim, Etacrynic acid may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Celecoxib.]
[A12CC05, magnesium aspartate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium aspartate.]
[N04AC01, benztropine, Etacrynic acid may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AX03, benzydamine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Benzydamine.]
[L01EE01, trametinib, Etacrynic acid may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX05, florbetapir F-18, Etacrynic acid may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX28, levomilnacipran, Etacrynic acid may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[C08EA02, bepridil, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bepridil.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Riociguat.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Etacrynic acid.]
[C02KX04, macitentan, Etacrynic acid may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX26, vortioxetine, Etacrynic acid may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC08, etonogestrel, Etacrynic acid may increase the excretion rate of Etonogestrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP08, sofosbuvir, Etacrynic acid may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Etacrynic acid.]
[C01CA27, droxidopa, The risk or severity of hypokalemia can be increased when Droxidopa is combined with Etacrynic acid.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acebutolol.]
[N05CH03, tasimelteon, Etacrynic acid may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA32, apremilast, Etacrynic acid may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BG02, formestane, Etacrynic acid may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA03, betamethasone, The risk or severity of hypokalemia can be increased when Betamethasone is combined with Etacrynic acid.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Etacrynic acid.]
[V03AB34, fomepizole, Etacrynic acid may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02CC01, bethanidine, Etacrynic acid may increase the hypotensive activities of Bethanidine.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Etacrynic acid.]
[B01AA07, acenocoumarol, The protein binding of Acenocoumarol can be decreased when combined with Etacrynic acid.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Etacrynic acid.]
[R03AC19, olodaterol, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Etacrynic acid.]
[V08AA01, diatrizoic acid, Etacrynic acid may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AA04, iothalamic acid, Etacrynic acid may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA15, dihydrostreptomycin, The serum concentration of Dihydrostreptomycin can be increased when it is combined with Etacrynic acid.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Phenolphthalein.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Etacrynic acid.]
[A06AH03, naloxegol, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naloxegol.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bisacodyl.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Etacrynic acid.]
[B01AA01, dicumarol, The protein binding of Dicoumarol can be decreased when combined with Etacrynic acid.]
[B01AF03, edoxaban, Etacrynic acid may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BE01, acetaminophen, Etacrynic acid may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC01, bleomycin, Etacrynic acid may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA11, tioclomarol, The protein binding of Tioclomarol can be decreased when combined with Etacrynic acid.]
[C01EB17, ivabradine, The risk or severity of Cardiac Arrhythmia can be increased when Etacrynic acid is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Etacrynic acid.]
[A07DA06, eluxadoline, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Eluxadoline.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium peroxide.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Etacrynic acid.]
[M02AA25, aceclofenac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Acemetacin.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Etacrynic acid.]
[V03AB37, idarucizumab, Etacrynic acid may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF13, tenofovir alafenamide, Etacrynic acid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01XG03, ixazomib, Etacrynic acid may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC27, selexipag, Etacrynic acid may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Etacrynic acid.]
[M04AB05, lesinurad, Etacrynic acid may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE16, alminoprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Alminoprofen.]
[N02BA02, aloxiprin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aloxiprin.]
[N03AX23, brivaracetam, Etacrynic acid may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA08, bromazepam, Etacrynic acid may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Etacrynic acid.]
[A02AD05, aluminum magnesium silicate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium Aluminum Silicate.]
[C08CA01, amlodipine, The risk or severity of adverse effects can be increased when Amlodipine is combined with Etacrynic acid.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Bumetanide is combined with Etacrynic acid.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Etacrynic acid.]
[C07AA19, bupranolol, Etacrynic acid may increase the hypotensive activities of Bupranolol.]
[N07BC01, buprenorphine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Buprenorphine.]
[N05BE01, buspirone, Etacrynic acid may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX27, arsenic trioxide, Etacrynic acid may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA03, clofezone, Etacrynic acid may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Butorphanol.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Plecanatide.]
[A07EC04, balsalazide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypokalemia can be increased when Bambuterol is combined with Etacrynic acid.]
[A06AH05, naldemedine, Etacrynic acid may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, Etacrynic acid may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, Etacrynic acid may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Etacrynic acid.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Etacrynic acid.]
[P01CA02, benznidazole, Etacrynic acid may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Etacrynic acid.]
[J05AF06, abacavir, Etacrynic acid may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX13, valbenazine, Etacrynic acid may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Etacrynic acid.]
[J01MA23, delafloxacin, Etacrynic acid may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC06, capecitabine, Etacrynic acid may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB07, bisoprolol, Etacrynic acid may increase the excretion rate of Bisoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC17, bitolterol, The risk or severity of hypokalemia can be increased when Bitolterol is combined with Etacrynic acid.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefprozil.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nesiritide.]
[R03BA02, budesonide, The risk or severity of hypokalemia can be increased when Budesonide is combined with Etacrynic acid.]
[M01AB07, bumadizone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Bumadizone.]
[C01AA02, acetyldigoxins, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Etacrynic acid.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Etacrynic acid.]
[R06AX18, acrivastine, Etacrynic acid may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Captopril.]
[L02BB05, apalutamide, Etacrynic acid may increase the excretion rate of Apalutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AF01, carbamazepine, Etacrynic acid may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A06AC08, calcium polycarbophil, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Calcium polycarbophil.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Etacrynic acid.]
[L04AA37, baricitinib, Etacrynic acid may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefpodoxime.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Ceftibuten.]
[J01GB14, plazomicin, The serum concentration of Plazomicin can be increased when it is combined with Etacrynic acid.]
[C07AB08, celiprolol, The risk or severity of hypokalemia can be increased when Celiprolol is combined with Etacrynic acid.]
[A16AX14, migalastat, Etacrynic acid may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, Etacrynic acid may increase the excretion rate of Stiripentol which could result in a lower serum level and potentially a reduction in efficacy.]
[S01GX12, cetirizine, Etacrynic acid may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Etacrynic acid.]
[D08AE05, chloroxylenol, Etacrynic acid may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC05, lornoxicam, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Inotersen.]
[L01AD01, carmustine, Etacrynic acid may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX05, prucalopride, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Prucalopride.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cilazapril.]
[B01AC23, cilostazol, Etacrynic acid may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA14, solriamfetol, Etacrynic acid may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA09, clobazam, Etacrynic acid may increase the excretion rate of Clobazam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01AA11, clomocycline, The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Etacrynic acid.]
[H02AB14, cloprednol, The risk or severity of hypokalemia can be increased when Cloprednol is combined with Etacrynic acid.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Castor oil.]
[C09CA06, candesartan, Etacrynic acid may increase the hypotensive activities of Candesartan.]
[H02AB17, cortivazol, The risk or severity of hypokalemia can be increased when Cortivazol is combined with Etacrynic acid.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Etacrynic acid.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefazolin.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Etacrynic acid.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefonicid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Etacrynic acid.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefotetan.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Etacrynic acid.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Etacrynic acid.]
[C03BX03, cicletanine, Etacrynic acid may increase the hypotensive activities of Cicletanine.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefuroxime.]
[N07XX11, pitolisant, Etacrynic acid may increase the excretion rate of Pitolisant which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA09, cyclothiazide, Etacrynic acid may increase the hypotensive activities of Cyclothiazide.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Etacrynic acid.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dantron.]
[J01XX09, daptomycin, Etacrynic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Etacrynic acid.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Etacrynic acid.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefapirin.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefradine.]
[H02AB13, deflazacort, The risk or severity of hypokalemia can be increased when Deflazacort is combined with Etacrynic acid.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Givosiran.]
[M09AX08, golodirsen, Etacrynic acid may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA12, dexpanthenol, Etacrynic acid may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX03, dezocine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dezocine.]
[L04AA53, teprotumumab, The risk or severity of ototoxicity can be increased when Etacrynic acid is combined with Teprotumumab.]
[R02AA03, dichlorobenzyl alcohol, Etacrynic acid may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, Etacrynic acid may increase the excretion rate of Dienogest which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dihydrocodeine.]
[M01AH02, rofecoxib, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Rofecoxib.]
[C08CA16, clevidipine, Etacrynic acid may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA06, methoserpidine, Etacrynic acid may increase the hypotensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Opicapone.]
[D07XB03, fluprednidene, The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Etacrynic acid.]
[M01AC04, droxicam, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Droxicam.]
[V08CA05, mangafodipir, Etacrynic acid may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA27, dexketoprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dexketoprofen.]
[C08CA17, levamlodipine, Etacrynic acid may increase the hypotensive activities of Levamlodipine.]
[N02AX07, oliceridine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, Etacrynic acid may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Etacrynic acid.]
[N05AA01, chlorpromazine, Etacrynic acid may increase the excretion rate of Chlorpromazine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etacrynic acid.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Etacrynic acid.]
[M03BB03, chlorzoxazone, Etacrynic acid may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA07, ethenzamide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ethenzamide.]
[N02BA03, choline salicylate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Choline salicylate.]
[M01AB08, etodolac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etodolac.]
[M02AA06, etofenamate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etofenamate.]
[M01AX25, chondroitin sulfates, Etacrynic acid may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Vericiguat.]
[M01AE05, fenbufen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Fenbufen.]
[C01CA19, fenoldopam, Etacrynic acid may increase the excretion rate of Fenoldopam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD15, cefdinir, Etacrynic acid may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[S01JA01, fluorescein, The excretion of Fluorescein can be decreased when combined with Etacrynic acid.]
[N02BG07, flupirtine, Etacrynic acid may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC15, formoterol, The risk or severity of hypokalemia can be increased when Formoterol is combined with Etacrynic acid.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Etacrynic acid.]
[H04AA02, dasiglucagon, Etacrynic acid may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, Etacrynic acid may increase the excretion rate of Cimetidine which could result in a lower serum level and potentially a reduction in efficacy.]
[V08CA04, gadoteridol, Etacrynic acid may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA07, ciprofloxacin, Etacrynic acid may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XA01, cisplatin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Etacrynic acid is combined with Cisplatin.]
[V09AB03, ioflupane I-123, Etacrynic acid may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AA01, technetium Tc 99m exametazime, Etacrynic acid may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX06, florbetaben f-18, Etacrynic acid may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Etacrynic acid.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Etacrynic acid.]
[R03CC13, clenbuterol, The risk or severity of hypokalemia can be increased when Clenbuterol is combined with Etacrynic acid.]
[J01FF01, clindamycin, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Clindamycin.]
[N01BB10, levobupivacaine, Etacrynic acid may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA04, clomipramine, Etacrynic acid may increase the excretion rate of Clomipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AE01, clonazepam, Etacrynic acid may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Clonidine is combined with Etacrynic acid.]
[J05AH02, oseltamivir, Etacrynic acid may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Etacrynic acid.]
[N05AH02, clozapine, Etacrynic acid may increase the excretion rate of Clozapine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Etacrynic acid.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Etacrynic acid.]
[J01GB12, arbekacin, The serum concentration of Arbekacin can be increased when it is combined with Etacrynic acid.]
[C02KB01, metyrosine, Etacrynic acid may increase the hypotensive activities of Metyrosine.]
[M01AX13, proquazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Proquazone.]
[R05DA04, codeine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Codeine.]
[M04AC01, colchicine, Etacrynic acid may increase the excretion rate of Colchicine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XB01, colistin, The serum concentration of Colistin can be increased when it is combined with Etacrynic acid.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefpirome.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Desflurane.]
[A04AA03, tropisetron, Etacrynic acid may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Etacrynic acid.]
[N02BA16, imidazole-2-hydroxybenzoate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Imidazole salicylate.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Etacrynic acid.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Etacrynic acid.]
[R03BA08, ciclesonide, The risk or severity of hypokalemia can be increased when Ciclesonide is combined with Etacrynic acid.]
[B01AC10, indobufen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indobufen.]
[J05AB14, valganciclovir, Etacrynic acid may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Etacrynic acid may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Etacrynic acid may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Etacrynic acid may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Etacrynic acid may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Etacrynic acid may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Valdecoxib.]
[C01AA06, lanatoside C, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lanatoside C.]
[N02CC05, almotriptan, Etacrynic acid may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH04, parecoxib, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Parecoxib.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Etacrynic acid.]
[N05BA10, ketazolam, Etacrynic acid may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AA06, kebuzone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Kebuzone.]
[C08CA09, lacidipine, Etacrynic acid may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lactitol.]
[N03AX09, lamotrigine, Etacrynic acid may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA03, cortisone, The risk or severity of hypokalemia can be increased when Cortisone is combined with Etacrynic acid.]
[N07BC04, lofexidine, Etacrynic acid may increase the excretion rate of Lofexidine which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB09, lonazolac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lonazolac.]
[M02AA31, loxoprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Loxoprofen.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Etacrynic acid.]
[C09AA03, lisinopril, Etacrynic acid may increase the excretion rate of Lisinopril which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium carbonate.]
[B05XA10, magnesium phosphate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium phosphate.]
[C08CA11, manidipine, Etacrynic acid may increase the hypotensive activities of Manidipine.]
[H02AB15, meprednisone, The risk or severity of hypokalemia can be increased when Meprednisone is combined with Etacrynic acid.]
[J01DH02, meropenem, Etacrynic acid may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Eplerenone is combined with Etacrynic acid.]
[N05AD03, metylperon, Etacrynic acid may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA07, cyclopenthiazide, Etacrynic acid may increase the hypotensive activities of Cyclopenthiazide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Etacrynic acid.]
[J05AF07, tenofovir disoproxil, Etacrynic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Etacrynic acid.]
[S01XA18, cyclosporine, The risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Etacrynic acid.]
[C09AA13, moexipril, The risk or severity of adverse effects can be increased when Moexipril is combined with Etacrynic acid.]
[M02AA02, mofebutazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mofebutazone.]
[M01AX22, morniflumate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Morniflumate.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Conivaptan is combined with Etacrynic acid.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Moxonidine.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Etacrynic acid.]
[M01AH05, etoricoxib, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etoricoxib.]
[L01AX04, dacarbazine, Etacrynic acid may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03CA01, dantrolene, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Dantrolene.]
[C02CC04, debrisoquin, Etacrynic acid may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Etacrynic acid.]
[M01AX01, nabumetone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nabumetone.]
[N07BB05, nalmefene, Etacrynic acid may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Potassium lactate.]
[J01AA01, demeclocycline, The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Etacrynic acid.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nebivolol.]
[S01GX04, nedocromil, Etacrynic acid may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, Etacrynic acid may increase the excretion rate of Nefazodone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Etacrynic acid.]
[L02BB02, nilutamide, Etacrynic acid may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Etacrynic acid.]
[M03AC11, cisatracurium, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Etacrynic acid.]
[R05DA06, normethadone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Etacrynic acid may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC03, olsalazine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Olsalazine.]
[N06AA01, desipramine, Etacrynic acid may increase the excretion rate of Desipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AA07, deslanoside, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Deslanoside.]
[H01BA02, desmopressin, Etacrynic acid may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XC02, desoximetasone, The risk or severity of hypokalemia can be increased when Desoximetasone is combined with Etacrynic acid.]
[V04CH02, indigo carmine, Etacrynic acid may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA03, desoxycorticosterone, The risk or severity of hypokalemia can be increased when Desoxycortone is combined with Etacrynic acid.]
[J01DH03, ertapenem, Etacrynic acid may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aliskiren.]
[M01AE12, oxaprozin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxaprozin.]
[S03BA01, dexamethasone, The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Etacrynic acid.]
[N06BA02, dextroamphetamine, Etacrynic acid may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AC01, dextromoramide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dextromoramide.]
[N07BC06, heroin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diamorphine.]
[P03AC04, permethrin, Etacrynic acid may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, Etacrynic acid may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Diazoxide.]
[R05DA08, pholcodine, Etacrynic acid may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA02, clodronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Diclofenamide.]
[S01BC03, diclofenac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diclofenac.]
[J05AD01, foscarnet, Etacrynic acid may decrease the excretion rate of Foscarnet which could result in a higher serum level.]
[A03AA07, dicyclomine, Etacrynic acid may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF03, zalcitabine, The excretion of Zalcitabine can be decreased when combined with Etacrynic acid.]
[J05AF02, didanosine, Etacrynic acid may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DG01, pinacidil, Etacrynic acid may increase the hypotensive activities of Pinacidil.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Etacrynic acid.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pipamperone.]
[R03CC07, pirbuterol, The risk or severity of hypokalemia can be increased when Pirbuterol is combined with Etacrynic acid.]
[C08CA03, isradipine, Etacrynic acid may increase the excretion rate of Isradipine which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XC04, diflucortolone, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Etacrynic acid.]
[N02BA11, diflunisal, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin.]
[C02DB01, dihydralazine, Etacrynic acid may increase the hypotensive activities of Dihydralazine.]
[N02AA03, hydromorphone, Etacrynic acid may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Etacrynic acid may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Atazanavir.]
[B01AC21, treprostinil, Etacrynic acid may increase the hypotensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, Etacrynic acid may increase the excretion rate of Potassium perchlorate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB04, pralidoxime, Etacrynic acid may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DB01, diltiazem, The risk or severity of adverse effects can be increased when Diltiazem is combined with Etacrynic acid.]
[V03AB09, dimercaprol, Etacrynic acid may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC08, procaterol, The risk or severity of hypokalemia can be increased when Procaterol is combined with Etacrynic acid.]
[M02AX03, dimethyl sulfoxide, Etacrynic acid may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Propyphenazone.]
[M01AB14, proglumetacin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Proglumetacin.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Etacrynic acid.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diphenoxylate.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Quinapril is combined with Etacrynic acid.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dipyridamole.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Etacrynic acid.]
[S01AX06, resorcinol, Etacrynic acid may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Etacrynic acid.]
[N05AX08, risperidone, The risk or severity of hypotension can be increased when Etacrynic acid is combined with Risperidone.]
[R06AE09, levocetirizine, Etacrynic acid may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB09, ropivacaine, Etacrynic acid may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Etacrynic acid.]
[G04BE08, tadalafil, Etacrynic acid may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC05, ketorolac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, Etacrynic acid may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, Etacrynic acid may increase the excretion rate of Ranolazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA06, salsalate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Etacrynic acid.]
[H05BA01, salmon calcitonin, Etacrynic acid may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, The risk or severity of hypokalemia can be increased when Dobutamine is combined with Etacrynic acid.]
[C01CA04, dopamine, Etacrynic acid may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA12, doxepin, Etacrynic acid may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sennosides.]
[J01AA02, doxycycline, Etacrynic acid may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sevoflurane.]
[A08AA10, sibutramine, Etacrynic acid may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AG05, sodium phosphate, Etacrynic acid may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sodium sulfate.]
[C09AA11, spirapril, Etacrynic acid may increase the hypotensive activities of Spirapril.]
[R03DA01, dyphylline, Etacrynic acid may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC01, sumatriptan, Etacrynic acid may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX07, edrophonium, Etacrynic acid may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, Etacrynic acid may increase the hypotensive activities of Talinolol.]
[H01AA01, corticotropin, The risk or severity of hypokalemia can be increased when Corticotropin is combined with Etacrynic acid.]
[J01CG02, tazobactam, The excretion of Tazobactam can be decreased when combined with Etacrynic acid.]
[L01AX03, temozolomide, Etacrynic acid may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tenoxicam.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Terazosin.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Enalapril is combined with Etacrynic acid.]
[M01AG02, tolfenamic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Etacrynic acid.]
[N06BA09, atomoxetine, Etacrynic acid may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX11, topiramate, The risk or severity of hypokalemia can be increased when Etacrynic acid is combined with Topiramate.]
[C03CA04, torsemide, The risk or severity of ototoxicity can be increased when Torasemide is combined with Etacrynic acid.]
[J01AA12, tigecycline, The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Etacrynic acid.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Etacrynic acid.]
[N05CC01, chloral hydrate, Etacrynic acid may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[H02CA01, trilostane, The risk or severity of hypokalemia can be increased when Trilostane is combined with Etacrynic acid.]
[C02CA06, urapidil, Etacrynic acid may increase the hypotensive activities of Urapidil.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Etacrynic acid.]
[N06AX16, venlafaxine, Etacrynic acid may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of hypokalemia can be increased when Epinephrine is combined with Etacrynic acid.]
[C09AA15, zofenopril, Etacrynic acid may increase the hypotensive activities of Zofenopril.]
[M01AB04, zomepirac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Zomepirac.]
[N03AX15, zonisamide, Etacrynic acid may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Etacrynic acid.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Carboplatin.]
[C02AC02, guanfacine, Etacrynic acid may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Iloprost.]
[L03AX05, pidotimod, Etacrynic acid may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD04, estazolam, Etacrynic acid may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Etacrynic acid may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA03, estradiol, Etacrynic acid may increase the excretion rate of Estradiol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA57, estrogens, conjugated (USP), Etacrynic acid may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA01, etidronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Etidronic acid.]
[M05BA04, alendronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Alendronic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Etacrynic acid.]
[C01DA14, isosorbide mononitrate, Etacrynic acid may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[D10AX03, azelaic acid, Etacrynic acid may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE11, tiaprofenic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tiaprofenic acid.]
[S02BA08, fluocinolone acetonide, Etacrynic acid may increase the excretion rate of Fluocinolone acetonide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AG01, mefenamic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Etacrynic acid may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, Etacrynic acid may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA09, fluticasone furoate, The risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Etacrynic acid.]
[V08CA03, gadodiamide, Etacrynic acid may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amifostine.]
[C01BD05, ibutilide, Etacrynic acid may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC06, meloxicam, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ethylmorphine.]
[N01AX07, etomidate, Etacrynic acid may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Etacrynic acid.]
[P01AX07, trimetrexate, Etacrynic acid may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, Etacrynic acid may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB08, fluvoxamine, Etacrynic acid may increase the excretion rate of Fluvoxamine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE02, leuprolide, Etacrynic acid may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01CB01, gold sodium thiomalate, Etacrynic acid may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, Etacrynic acid may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF02, dexrazoxane, Etacrynic acid may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA01, levocarnitine, Etacrynic acid may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA02, felodipine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.]
[M01AE04, fenoprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of hypokalemia can be increased when Fenoterol is combined with Etacrynic acid.]
[N02AB03, fentanyl, Etacrynic acid may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, The risk or severity of hypokalemia can be increased when Salbutamol is combined with Etacrynic acid.]
[L01BB06, clofarabine, Etacrynic acid may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07AX03, cevimeline, Etacrynic acid may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Etacrynic acid may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG04, floctafenine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Floctafenine.]
[J02AC01, fluconazole, Etacrynic acid may increase the excretion rate of Fluconazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AX01, flucytosine, Etacrynic acid may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA02, fludrocortisone, The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Etacrynic acid.]
[V03AB25, flumazenil, Etacrynic acid may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XB01, flumethasone, The risk or severity of hypokalemia can be increased when Flumethasone is combined with Etacrynic acid.]
[D07AC08, fluocinonide, The risk or severity of hypokalemia can be increased when Fluocinonide is combined with Etacrynic acid.]
[H02AB03, fluocortolone, The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Etacrynic acid.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Etacrynic acid.]
[L01BC09, floxuridine, Etacrynic acid may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD01, flurazepam, Etacrynic acid may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Flurbiprofen.]
[L02BB01, flutamide, Etacrynic acid may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Etacrynic acid may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Etacrynic acid may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA07, framycetin, The serum concentration of Framycetin can be increased when it is combined with Etacrynic acid.]
[L01BC03, tegafur, Etacrynic acid may increase the excretion rate of Tegafur which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AA01, alcuronium, The therapeutic efficacy of Alcuronium can be increased when used in combination with Etacrynic acid.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Etacrynic acid.]
[C03CA01, furosemide, Furosemide may increase the ototoxic activities of Etacrynic acid.]
[N05CF04, eszopiclone, Etacrynic acid may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC02, gallamine, The therapeutic efficacy of Gallamine can be increased when used in combination with Etacrynic acid.]
[S01AD09, ganciclovir, Etacrynic acid may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Etacrynic acid.]
[C10AB04, gemfibrozil, Etacrynic acid may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XA03, telavancin, Etacrynic acid may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Etacrynic acid.]
[N01AH02, alfentanil, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Alfentanil.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Etacrynic acid.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Etacrynic acid.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Etacrynic acid.]
[N05CM18, dexmedetomidine, Etacrynic acid may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Glycerin.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Etacrynic acid.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Etacrynic acid is combined with Dofetilide.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Etacrynic acid.]
[L01EX02, sorafenib, Etacrynic acid may increase the excretion rate of Sorafenib which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Etacrynic acid.]
[M01CB04, aurothioglucose, Etacrynic acid may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Etacrynic acid may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA12, fluindione, The protein binding of Fluindione can be decreased when combined with Etacrynic acid.]
[C09AA09, fosinopril, Etacrynic acid may increase the excretion rate of Fosinopril which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EX01, guanethidine, Etacrynic acid may increase the excretion rate of Guanethidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE03, goserelin, Etacrynic acid may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD01, haloperidol, Etacrynic acid may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Halothane.]
[N05AH04, quetiapine, Etacrynic acid may increase the excretion rate of Quetiapine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX13, idebenone, Etacrynic acid may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Etacrynic acid.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Allopurinol.]
[C09CA01, losartan, The risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium citrate.]
[A12CC03, magnesium gluconate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium gluconate.]
[G03DC01, allylestrenol, Etacrynic acid may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Etacrynic acid.]
[C01CE02, milrinone, Etacrynic acid may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sodium fluorophosphate.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Etacrynic acid.]
[R03CC05, hexoprenaline, The risk or severity of hypokalemia can be increased when Hexoprenaline is combined with Etacrynic acid.]
[C08CA10, nilvadipine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nilvadipine.]
[M02AA26, nimesulide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nimesulide.]
[C09AA04, perindopril, Etacrynic acid may increase the excretion rate of Perindopril which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DB02, hydralazine, Etacrynic acid may increase the excretion rate of Hydralazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Etacrynic acid.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Etacrynic acid.]
[B05XA17, potassium acetate, Etacrynic acid may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Etacrynic acid may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Etacrynic acid may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA07, hetastarch, Etacrynic acid may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC06, rilmenidine, Etacrynic acid may increase the hypotensive activities of Rilmenidine.]
[M05BA07, risedronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Risedronic acid.]
[R02AX02, ibuprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ibuprofen.]
[B05XA08, sodium acetate, Etacrynic acid may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sodium tartrate.]
[L01AA06, ifosfamide, Etacrynic acid may increase the excretion rate of Ifosfamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AH03, sufentanil, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, Etacrynic acid may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Paclitaxel.]
[R01AD07, tixocortol, Etacrynic acid may increase the excretion rate of Tixocortol which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Etacrynic acid.]
[L01CE01, topotecan, Etacrynic acid may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, Etacrynic acid may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indomethacin.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Indoramin.]
[A11HA07, inositol, Etacrynic acid may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, Etacrynic acid may increase the excretion rate of Milnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA02, cyclopentamine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cyclopentamine.]
[S01XA28, varenicline, Etacrynic acid may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Etacrynic acid.]
[N05BA12, alprazolam, Etacrynic acid may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Etacrynic acid may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Etacrynic acid.]
[C07AA01, alprenolol, Etacrynic acid may increase the hypotensive activities of Alprenolol.]
[V03AB01, ipecac, Etacrynic acid may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF04, stavudine, The excretion of Stavudine can be decreased when combined with Etacrynic acid.]
[G04BE01, alprostadil, The excretion of Alprostadil can be decreased when combined with Etacrynic acid.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Etacrynic acid.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Etacrynic acid.]
[R03CC06, isoetharine, The risk or severity of hypokalemia can be increased when Isoetharine is combined with Etacrynic acid.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Etacrynic acid.]
[J04AC01, isoniazid, Etacrynic acid may increase the excretion rate of Isoniazid which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AX05, inosine pranobex, Etacrynic acid may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB01, isoproterenol, The risk or severity of hypokalemia can be increased when Isoprenaline is combined with Etacrynic acid.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Etacrynic acid.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Etacrynic acid.]
[D10BA01, isotretinoin, Etacrynic acid may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isoxsuprine.]
[S01AA24, kanamycin, The serum concentration of Kanamycin can be increased when it is combined with Etacrynic acid.]
[N01AX03, ketamine, Etacrynic acid may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KD01, ketanserin, Etacrynic acid may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, Etacrynic acid may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Etacrynic acid.]
[M02AA10, ketoprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketoprofen.]
[C01CA22, arbutamine, The risk or severity of hypokalemia can be increased when Arbutamine is combined with Etacrynic acid.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Rotigotine.]
[C07AG01, labetalol, Etacrynic acid may increase the excretion rate of Labetalol which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BB01, amantadine, Etacrynic acid may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA05, deserpidine, Etacrynic acid may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lubiprostone.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Etacrynic acid is combined with Levodopa.]
[J01FF02, lincomycin, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Lincomycin.]
[S01AA21, amikacin, The serum concentration of Amikacin can be increased when it is combined with Etacrynic acid.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Etacrynic acid.]
[N05BA06, lorazepam, Etacrynic acid may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01AA04, lymecycline, The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Etacrynic acid.]
[B05XA11, magnesium chloride, Etacrynic acid may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Etacrynic acid may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Etacrynic acid.]
[N06AA21, maprotiline, Etacrynic acid may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Mecamylamine.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meclofenamic acid.]
[C01AA08, medigoxin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metildigoxin.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Frangula purshiana bark.]
[N06DX01, memantine, Etacrynic acid may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, Etacrynic acid may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Etacrynic acid.]
[N01BB03, mepivacaine, Etacrynic acid may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Etacrynic acid may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BC01, mersalyl, Etacrynic acid may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Etacrynic acid may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid.]
[J01AA05, methacycline, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Metacycline.]
[N07BC02, methadone, Etacrynic acid may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA03, methamphetamine, Etacrynic acid may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF05, lamivudine, Etacrynic acid may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Etacrynic acid.]
[H03BB02, methimazole, Etacrynic acid may increase the excretion rate of Methimazole which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BA04, pemetrexed, Etacrynic acid may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Etacrynic acid.]
[A11HA02, pyridoxine, Etacrynic acid may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Etacrynic acid is combined with Ziconotide.]
[L04AX03, methotrexate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methotrexate.]
[D05BA02, methoxsalen, Etacrynic acid may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Methylcellulose.]
[C02AB01, methyldopa, Etacrynic acid may increase the excretion rate of Methyldopa which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Etacrynic acid.]
[H02AB04, methylprednisolone, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Etacrynic acid.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Etacrynic acid.]
[G03EK01, methyltestosterone, Etacrynic acid may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA01, metoclopramide, Etacrynic acid may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, Etacrynic acid may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Etacrynic acid may increase the excretion rate of Metoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CD01, metyrapone, Etacrynic acid may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB03, aminopyrine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Aminophenazone.]
[N05CD08, midazolam, Etacrynic acid may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Etacrynic acid.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Mineral oil.]
[J05AH01, zanamivir, Etacrynic acid may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid.]
[J01AA08, minocycline, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Minocycline.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Etacrynic acid.]
[L03AC01, aldesleukin, Etacrynic acid may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amiodarone.]
[N06AA09, amitriptyline, Etacrynic acid may increase the excretion rate of Amitriptyline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA01, morphine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Morphine.]
[A04AA05, palonosetron, Etacrynic acid may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Etacrynic acid may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BA01, ammonium chloride, Etacrynic acid may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA06, mycophenolic acid, Etacrynic acid may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC03, vecuronium, The therapeutic efficacy of Vecuronium can be increased when used in combination with Etacrynic acid.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Etacrynic acid.]
[C07AA12, nadolol, Etacrynic acid may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA04, amoxicillin, Etacrynic acid may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Etacrynic acid.]
[N02AF02, nalbuphine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, Etacrynic acid may increase the excretion rate of Naloxone which could result in a lower serum level and potentially a reduction in efficacy.]
[N07BB04, naltrexone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naltrexone.]
[N06BA01, amphetamine, Etacrynic acid may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naproxen.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Etacrynic acid.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Etacrynic acid is combined with Duloxetine.]
[N04BX01, tolcapone, Etacrynic acid may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Neomycin.]
[N01AH06, remifentanil, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Remifentanil.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Etacrynic acid.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Levosimendan.]
[B01AC17, tirofiban, Etacrynic acid may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Etacrynic acid.]
[S01AA19, ampicillin, Etacrynic acid may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Etacrynic acid may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA23, netilmicin, The serum concentration of Netilmicin can be increased when it is combined with Etacrynic acid.]
[N06AX23, desvenlafaxine, Etacrynic acid may increase the excretion rate of Desvenlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Telmisartan.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Etacrynic acid.]
[C01CE01, inamrinone, Etacrynic acid may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Etacrynic acid.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Etacrynic acid.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nicotine.]
[C08CA05, nifedipine, Etacrynic acid may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA17, niflumic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of adverse effects can be increased when Nimodipine is combined with Etacrynic acid.]
[C08CA07, nisoldipine, Etacrynic acid may increase the excretion rate of Nisoldipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA08, nitrendipine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nitrendipine.]
[R07AX01, nitric oxide, Etacrynic acid may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Etacrynic acid may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF03, zaleplon, Etacrynic acid may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Etacrynic acid may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, Etacrynic acid may increase the excretion rate of Nitroprusside which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA03, norepinephrine, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Etacrynic acid.]
[C02KX01, bosentan, Etacrynic acid may increase the hypotensive activities of Bosentan.]
[N02AA02, opium, Etacrynic acid may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB03, metaproterenol, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Etacrynic acid.]
[G04CA02, tamsulosin, Etacrynic acid may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AC01, ouabain, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ouabain.]
[M05BA08, zoledronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Zoledronic acid.]
[J01CF04, oxacillin, Etacrynic acid may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA04, oxazepam, Etacrynic acid may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxycodone.]
[N02AA11, oxymorphone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxymorphone.]
[S01BC02, oxyphenbutazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxyphenbutazone.]
[S01AA04, oxytetracycline, The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Etacrynic acid.]
[V04CH30, 4-aminohippuric acid, The excretion of Aminohippuric acid can be decreased when combined with Etacrynic acid.]
[J04AA01, aminosalicylic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aminosalicylic acid.]
[N02AX06, tapentadol, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tapentadol.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be increased when used in combination with Etacrynic acid.]
[J04AB30, capreomycin, The serum concentration of Capreomycin can be increased when it is combined with Etacrynic acid.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of hypokalemia can be increased when Paramethasone is combined with Etacrynic acid.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Etacrynic acid.]
[A07AA06, paromomycin, The serum concentration of Paromomycin can be increased when it is combined with Etacrynic acid.]
[G04BD11, fesoterodine, Etacrynic acid may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, Etacrynic acid may increase the excretion rate of Penbutolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CE09, penicillin G procaine, Etacrynic acid may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AD01, pentazocine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Etacrynic acid.]
[L01XX08, pentostatin, Etacrynic acid may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Etacrynic acid may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AD02, phenazocine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Phenazopyridine.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Etacrynic acid.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Etacrynic acid.]
[B01AA02, phenindione, The protein binding of Phenindione can be decreased when combined with Etacrynic acid.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Etacrynic acid.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The protein binding of Phenprocoumon can be decreased when combined with Etacrynic acid.]
[V03AB36, phentolamine, Etacrynic acid may increase the excretion rate of Phentolamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA01, phenylbutazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenylbutazone.]
[R01BA01, phenylpropanolamine, The risk or severity of hypokalemia can be increased when Phenylpropanolamine is combined with Etacrynic acid.]
[S01AE05, levofloxacin, Etacrynic acid may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B02BA01, vitamin K1, Etacrynic acid may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Etacrynic acid.]
[C08CX01, mibefradil, Etacrynic acid may increase the hypotensive activities of Mibefradil.]
[C07AA03, pindolol, Etacrynic acid may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA12, piperacillin, Etacrynic acid may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX03, piracetam, Etacrynic acid may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Eprosartan is combined with Etacrynic acid.]
[N02AC03, pirinitramide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Piroxicam.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefditoren.]
[J01MA11, grepafloxacin, The excretion of Grepafloxacin can be decreased when combined with Etacrynic acid.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Irbesartan.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Etacrynic acid.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Polyethylene glycol.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Polymyxin B.]
[C03AA05, polythiazide, Etacrynic acid may increase the hypotensive activities of Polythiazide.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Etacrynic acid.]
[B05XA01, potassium chloride, Etacrynic acid may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Etacrynic acid.]
[C07AB01, practolol, Etacrynic acid may increase the hypotensive activities of Practolol.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Etacrynic acid.]
[S03BA02, prednisolone, The risk or severity of hypokalemia can be increased when Prednisolone is combined with Etacrynic acid.]
[H02AB07, prednisone, The risk or severity of hypokalemia can be increased when Prednisone is combined with Etacrynic acid.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Etacrynic acid.]
[M04AB01, probenecid, The risk or severity of adverse effects can be increased when Probenecid is combined with Etacrynic acid.]
[C01BA02, procainamide, Etacrynic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, Procaine may increase the orthostatic hypotensive activities of Etacrynic acid.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Etacrynic acid.]
[C10AB05, fenofibrate, Etacrynic acid may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD02, promethazine, Etacrynic acid may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB05, propantheline, Etacrynic acid may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Etacrynic acid.]
[N02AC04, propoxyphene, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dextropropoxyphene.]
[C07AA05, propranolol, Etacrynic acid may increase the excretion rate of Propranolol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AB01, proscillaridin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Proscillaridin.]
[N02CC04, rizatriptan, Etacrynic acid may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, Etacrynic acid may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX12, aripiprazole, Aripiprazole may increase the hypotensive activities of Etacrynic acid.]
[N07XX07, dalfampridine, Etacrynic acid may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CC01, pyrantel, The therapeutic efficacy of Pyrantel can be increased when used in combination with Etacrynic acid.]
[J04AK01, pyrazinamide, Etacrynic acid may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA01, quinidine, Etacrynic acid may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Etacrynic acid.]
[A02BA02, ranitidine, Etacrynic acid may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, Etacrynic acid may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, Etacrynic acid may increase the excretion rate of Reserpine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP01, ribavirin, Etacrynic acid may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CA01, ritodrine, The risk or severity of hypokalemia can be increased when Ritodrine is combined with Etacrynic acid.]
[J01AA09, rolitetracycline, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Rolitetracycline.]
[N02BA05, salicylamide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salicylic acid.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Etacrynic acid.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Etacrynic acid.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Obinutuzumab.]
[J01GB08, sisomicin, The serum concentration of Sisomicin can be increased when it is combined with Etacrynic acid.]
[A12CD01, sodium fluoride, Etacrynic acid may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sorbitol.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Etacrynic acid.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Etacrynic acid.]
[S02DA03, antipyrine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Etacrynic acid.]
[J01GA01, streptomycin, The serum concentration of Streptomycin can be increased when it is combined with Etacrynic acid.]
[M03AB01, succinylcholine, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Etacrynic acid.]
[A02BX02, sucralfate, Etacrynic acid may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Etacrynic acid may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Etacrynic acid.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Etacrynic acid.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Etacrynic acid.]
[M01AB02, sulindac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sulindac.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Etacrynic acid.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Etacrynic acid.]
[M01AX04, apazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Azapropazone.]
[N05CD07, temazepam, Etacrynic acid may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC03, terbutaline, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Etacrynic acid.]
[B01AE07, dabigatran etexilate, Etacrynic acid may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BA03, testosterone, Etacrynic acid may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA02, tetracycline, Etacrynic acid may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Ceftaroline fosamil.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Etacrynic acid.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Thalidomide.]
[P02CA02, thiabendazole, Etacrynic acid may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, Etacrynic acid may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Etacrynic acid.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Etacrynic acid.]
[G04BE06, moxisylyte, Etacrynic acid may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Etacrynic acid may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC05, ticlopidine, Etacrynic acid may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, Etacrynic acid may increase the excretion rate of Timolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01AB02, tinidazole, Etacrynic acid may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA12, tobramycin, The serum concentration of Tobramycin can be increased when it is combined with Etacrynic acid.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Etacrynic acid.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Tolazoline is combined with Etacrynic acid.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Etacrynic acid.]
[M02AA21, tolmetin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tolmetin.]
[N02AX02, tramadol, Etacrynic acid may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Etacrynic acid.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Etacrynic acid.]
[S01BA05, triamcinolone, The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Etacrynic acid.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Etacrynic acid.]
[N05CD05, triazolam, Etacrynic acid may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA06, trichlormethiazide, Etacrynic acid may increase the hypotensive activities of Trichlormethiazide.]
[A16AX12, trientine, Etacrynic acid may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AD02, trifluridine, Etacrynic acid may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC02, fluclorolone, The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Etacrynic acid.]
[A03AA05, trimebutine, Etacrynic acid may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Trimethaphan.]
[J01EA01, trimethoprim, Etacrynic acid may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, The therapeutic efficacy of Tubocurarine can be increased when used in combination with Etacrynic acid.]
[R03DX07, roflumilast, Etacrynic acid may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX04, ipilimumab, Etacrynic acid may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AA14, oxyquinoline, Etacrynic acid may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etacrynic acid.]
[S01AA28, vancomycin, Etacrynic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Etacrynic acid may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF01, rivaroxaban, Etacrynic acid may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC18, indacaterol, The risk or severity of hypokalemia can be increased when Indacaterol is combined with Etacrynic acid.]
[C08DA01, verapamil, Etacrynic acid may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX09, viloxazine, Etacrynic acid may increase the excretion rate of Viloxazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX07, vincamine, Etacrynic acid may increase the hypotensive activities of Vincamine.]
[B03BA01, vitamin B12, Etacrynic acid may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA03, warfarin, The protein binding of Warfarin can be decreased when combined with Etacrynic acid.]
[C03BA10, xipamide, Etacrynic acid may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The excretion of Zidovudine can be decreased when combined with Etacrynic acid.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Etacrynic acid.]
[M05BA05, tiludronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Tiludronic acid.]
[B06AC02, icatibant, Etacrynic acid may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC04, rabeprazole, Etacrynic acid may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA06, ibandronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Ibandronate.]
[V03AC02, deferiprone, Etacrynic acid may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Etacrynic acid which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Etacrynic acid may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD07, tolterodine, Etacrynic acid may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH04, doripenem, Etacrynic acid may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Atenolol is combined with Etacrynic acid.]
[M03AC04, atracurium, The therapeutic efficacy of Atracurium can be increased when used in combination with Etacrynic acid.]
[M01CB03, auranofin, Etacrynic acid may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB11, prednylidene, The risk or severity of hypokalemia can be increased when Prednylidene is combined with Etacrynic acid.]
[B03XA04, peginesatide, Etacrynic acid may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Etacrynic acid may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Etacrynic acid may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, Etacrynic acid may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DF01, aztreonam, Etacrynic acid may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Etacrynic acid.]
[G04BE10, avanafil, The risk or severity of hypotension can be increased when Avanafil is combined with Etacrynic acid.]
[M03BX01, baclofen, Etacrynic acid may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[A08AA11, lorcaserin, Etacrynic acid may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD12, mirabegron, Etacrynic acid may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BB04, enzalutamide, Etacrynic acid may increase the excretion rate of Enzalutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Linaclotide.]
[A02AA05, magnesium silicate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium silicate.]
[H02AA01, aldosterone, The risk or severity of hypokalemia can be increased when Aldosterone is combined with Etacrynic acid.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Etacrynic acid.]
[C01AA01, acetyldigitoxin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigitoxin.]
[D02BA02, octinoxate, Etacrynic acid may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Etacrynic acid.]
[C08CA13, lercanidipine, The risk or severity of adverse effects can be increased when Lercanidipine is combined with Etacrynic acid.]
[V09IX04, fluorodeoxyglucose F18, Etacrynic acid may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE03, sildenafil, The risk or severity of hypotension can be increased when Sildenafil is combined with Etacrynic acid.]
[V08CA11, gadofosveset, Etacrynic acid may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX08, teduglutide, Etacrynic acid may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Etacrynic acid.]
[A16AX09, glycerol phenylbutyrate, Etacrynic acid may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Etacrynic acid.]
[L04AX06, pomalidomide, Etacrynic acid may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA10, benorilate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of hypotension can be increased when Canagliflozin is combined with Etacrynic acid.]
[A12CC09, magnesium orotate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium orotate.]
[A06AX06, tegaserod, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tegaserod.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Etacrynic acid.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Etacrynic acid.]
[L03AA12, ancestim, Etacrynic acid may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Celecoxib.]
[A12CC05, magnesium aspartate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium aspartate.]
[N04AC01, benztropine, Etacrynic acid may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AX03, benzydamine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Benzydamine.]
[L01EE01, trametinib, Etacrynic acid may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX05, florbetapir F-18, Etacrynic acid may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX28, levomilnacipran, Etacrynic acid may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[C08EA02, bepridil, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bepridil.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Riociguat.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Etacrynic acid.]
[C02KX04, macitentan, Etacrynic acid may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX26, vortioxetine, Etacrynic acid may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC08, etonogestrel, Etacrynic acid may increase the excretion rate of Etonogestrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP08, sofosbuvir, Etacrynic acid may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Etacrynic acid.]
[C01CA27, droxidopa, The risk or severity of hypokalemia can be increased when Droxidopa is combined with Etacrynic acid.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acebutolol.]
[N05CH03, tasimelteon, Etacrynic acid may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA32, apremilast, Etacrynic acid may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BG02, formestane, Etacrynic acid may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA03, betamethasone, The risk or severity of hypokalemia can be increased when Betamethasone is combined with Etacrynic acid.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Etacrynic acid.]
[V03AB34, fomepizole, Etacrynic acid may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02CC01, bethanidine, Etacrynic acid may increase the hypotensive activities of Bethanidine.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Etacrynic acid.]
[B01AA07, acenocoumarol, The protein binding of Acenocoumarol can be decreased when combined with Etacrynic acid.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Etacrynic acid.]
[R03AC19, olodaterol, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Etacrynic acid.]
[V08AA01, diatrizoic acid, Etacrynic acid may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AA04, iothalamic acid, Etacrynic acid may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA15, dihydrostreptomycin, The serum concentration of Dihydrostreptomycin can be increased when it is combined with Etacrynic acid.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Phenolphthalein.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Etacrynic acid.]
[A06AH03, naloxegol, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naloxegol.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bisacodyl.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Etacrynic acid.]
[B01AA01, dicumarol, The protein binding of Dicoumarol can be decreased when combined with Etacrynic acid.]
[B01AF03, edoxaban, Etacrynic acid may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BE01, acetaminophen, Etacrynic acid may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC01, bleomycin, Etacrynic acid may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA11, tioclomarol, The protein binding of Tioclomarol can be decreased when combined with Etacrynic acid.]
[C01EB17, ivabradine, The risk or severity of Cardiac Arrhythmia can be increased when Etacrynic acid is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Etacrynic acid.]
[A07DA06, eluxadoline, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Eluxadoline.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium peroxide.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Etacrynic acid.]
[M02AA25, aceclofenac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Acemetacin.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Etacrynic acid.]
[V03AB37, idarucizumab, Etacrynic acid may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF13, tenofovir alafenamide, Etacrynic acid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01XG03, ixazomib, Etacrynic acid may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC27, selexipag, Etacrynic acid may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Etacrynic acid.]
[M04AB05, lesinurad, Etacrynic acid may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE16, alminoprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Alminoprofen.]
[N02BA02, aloxiprin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aloxiprin.]
[N03AX23, brivaracetam, Etacrynic acid may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA08, bromazepam, Etacrynic acid may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Etacrynic acid.]
[A02AD05, aluminum magnesium silicate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium Aluminum Silicate.]
[C08CA01, amlodipine, The risk or severity of adverse effects can be increased when Amlodipine is combined with Etacrynic acid.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Bumetanide is combined with Etacrynic acid.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Etacrynic acid.]
[C07AA19, bupranolol, Etacrynic acid may increase the hypotensive activities of Bupranolol.]
[N07BC01, buprenorphine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Buprenorphine.]
[N05BE01, buspirone, Etacrynic acid may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX27, arsenic trioxide, Etacrynic acid may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA03, clofezone, Etacrynic acid may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Butorphanol.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Plecanatide.]
[A07EC04, balsalazide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypokalemia can be increased when Bambuterol is combined with Etacrynic acid.]
[A06AH05, naldemedine, Etacrynic acid may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, Etacrynic acid may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, Etacrynic acid may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Etacrynic acid.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Etacrynic acid.]
[P01CA02, benznidazole, Etacrynic acid may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Etacrynic acid.]
[J05AF06, abacavir, Etacrynic acid may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX13, valbenazine, Etacrynic acid may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Etacrynic acid.]
[J01MA23, delafloxacin, Etacrynic acid may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC06, capecitabine, Etacrynic acid may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB07, bisoprolol, Etacrynic acid may increase the excretion rate of Bisoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC17, bitolterol, The risk or severity of hypokalemia can be increased when Bitolterol is combined with Etacrynic acid.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefprozil.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nesiritide.]
[R03BA02, budesonide, The risk or severity of hypokalemia can be increased when Budesonide is combined with Etacrynic acid.]
[M01AB07, bumadizone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Bumadizone.]
[C01AA02, acetyldigoxins, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Etacrynic acid.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Etacrynic acid.]
[R06AX18, acrivastine, Etacrynic acid may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Captopril.]
[L02BB05, apalutamide, Etacrynic acid may increase the excretion rate of Apalutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AF01, carbamazepine, Etacrynic acid may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A06AC08, calcium polycarbophil, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Calcium polycarbophil.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Etacrynic acid.]
[L04AA37, baricitinib, Etacrynic acid may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefpodoxime.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Ceftibuten.]
[J01GB14, plazomicin, The serum concentration of Plazomicin can be increased when it is combined with Etacrynic acid.]
[C07AB08, celiprolol, The risk or severity of hypokalemia can be increased when Celiprolol is combined with Etacrynic acid.]
[A16AX14, migalastat, Etacrynic acid may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, Etacrynic acid may increase the excretion rate of Stiripentol which could result in a lower serum level and potentially a reduction in efficacy.]
[S01GX12, cetirizine, Etacrynic acid may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Etacrynic acid.]
[D08AE05, chloroxylenol, Etacrynic acid may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC05, lornoxicam, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Inotersen.]
[L01AD01, carmustine, Etacrynic acid may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX05, prucalopride, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Prucalopride.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cilazapril.]
[B01AC23, cilostazol, Etacrynic acid may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA14, solriamfetol, Etacrynic acid may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA09, clobazam, Etacrynic acid may increase the excretion rate of Clobazam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01AA11, clomocycline, The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Etacrynic acid.]
[H02AB14, cloprednol, The risk or severity of hypokalemia can be increased when Cloprednol is combined with Etacrynic acid.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Castor oil.]
[C09CA06, candesartan, Etacrynic acid may increase the hypotensive activities of Candesartan.]
[H02AB17, cortivazol, The risk or severity of hypokalemia can be increased when Cortivazol is combined with Etacrynic acid.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Etacrynic acid.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefazolin.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Etacrynic acid.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefonicid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Etacrynic acid.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefotetan.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Etacrynic acid.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Etacrynic acid.]
[C03BX03, cicletanine, Etacrynic acid may increase the hypotensive activities of Cicletanine.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefuroxime.]
[N07XX11, pitolisant, Etacrynic acid may increase the excretion rate of Pitolisant which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA09, cyclothiazide, Etacrynic acid may increase the hypotensive activities of Cyclothiazide.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Etacrynic acid.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dantron.]
[J01XX09, daptomycin, Etacrynic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Etacrynic acid.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Etacrynic acid.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefapirin.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefradine.]
[H02AB13, deflazacort, The risk or severity of hypokalemia can be increased when Deflazacort is combined with Etacrynic acid.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Givosiran.]
[M09AX08, golodirsen, Etacrynic acid may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA12, dexpanthenol, Etacrynic acid may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX03, dezocine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dezocine.]
[L04AA53, teprotumumab, The risk or severity of ototoxicity can be increased when Etacrynic acid is combined with Teprotumumab.]
[R02AA03, dichlorobenzyl alcohol, Etacrynic acid may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, Etacrynic acid may increase the excretion rate of Dienogest which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dihydrocodeine.]
[M01AH02, rofecoxib, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Rofecoxib.]
[C08CA16, clevidipine, Etacrynic acid may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA06, methoserpidine, Etacrynic acid may increase the hypotensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Opicapone.]
[D07XB03, fluprednidene, The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Etacrynic acid.]
[M01AC04, droxicam, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Droxicam.]
[V08CA05, mangafodipir, Etacrynic acid may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA27, dexketoprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dexketoprofen.]
[C08CA17, levamlodipine, Etacrynic acid may increase the hypotensive activities of Levamlodipine.]
[N02AX07, oliceridine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, Etacrynic acid may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Etacrynic acid.]
[N05AA01, chlorpromazine, Etacrynic acid may increase the excretion rate of Chlorpromazine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etacrynic acid.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Etacrynic acid.]
[M03BB03, chlorzoxazone, Etacrynic acid may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA07, ethenzamide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ethenzamide.]
[N02BA03, choline salicylate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Choline salicylate.]
[M01AB08, etodolac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etodolac.]
[M02AA06, etofenamate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etofenamate.]
[M01AX25, chondroitin sulfates, Etacrynic acid may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Vericiguat.]
[M01AE05, fenbufen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Fenbufen.]
[C01CA19, fenoldopam, Etacrynic acid may increase the excretion rate of Fenoldopam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD15, cefdinir, Etacrynic acid may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[S02BA08, fluocinolone acetonide, Etacrynic acid may increase the excretion rate of Fluocinolone acetonide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01JA01, fluorescein, The excretion of Fluorescein can be decreased when combined with Etacrynic acid.]
[N02BG07, flupirtine, Etacrynic acid may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC15, formoterol, The risk or severity of hypokalemia can be increased when Formoterol is combined with Etacrynic acid.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Etacrynic acid.]
[H04AA02, dasiglucagon, Etacrynic acid may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, Etacrynic acid may increase the excretion rate of Cimetidine which could result in a lower serum level and potentially a reduction in efficacy.]
[V08CA04, gadoteridol, Etacrynic acid may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA07, ciprofloxacin, Etacrynic acid may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XA01, cisplatin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Etacrynic acid is combined with Cisplatin.]
[V09AB03, ioflupane I-123, Etacrynic acid may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AA01, technetium Tc 99m exametazime, Etacrynic acid may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX06, florbetaben f-18, Etacrynic acid may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Etacrynic acid.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Etacrynic acid.]
[R03CC13, clenbuterol, The risk or severity of hypokalemia can be increased when Clenbuterol is combined with Etacrynic acid.]
[J01FF01, clindamycin, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Clindamycin.]
[N01BB10, levobupivacaine, Etacrynic acid may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA04, clomipramine, Etacrynic acid may increase the excretion rate of Clomipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AE01, clonazepam, Etacrynic acid may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Clonidine is combined with Etacrynic acid.]
[J05AH02, oseltamivir, Etacrynic acid may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Etacrynic acid.]
[N05AH02, clozapine, Etacrynic acid may increase the excretion rate of Clozapine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Etacrynic acid.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Etacrynic acid.]
[J01GB12, arbekacin, The serum concentration of Arbekacin can be increased when it is combined with Etacrynic acid.]
[C02KB01, metyrosine, Etacrynic acid may increase the hypotensive activities of Metyrosine.]
[M01AX13, proquazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Proquazone.]
[R05DA04, codeine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Codeine.]
[M04AC01, colchicine, Etacrynic acid may increase the excretion rate of Colchicine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XB01, colistin, The serum concentration of Colistin can be increased when it is combined with Etacrynic acid.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefpirome.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Desflurane.]
[A04AA03, tropisetron, Etacrynic acid may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Etacrynic acid.]
[N02BA16, imidazole-2-hydroxybenzoate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Imidazole salicylate.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Etacrynic acid.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Etacrynic acid.]
[R03BA08, ciclesonide, The risk or severity of hypokalemia can be increased when Ciclesonide is combined with Etacrynic acid.]
[B01AC10, indobufen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indobufen.]
[J05AB14, valganciclovir, Etacrynic acid may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Etacrynic acid may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Etacrynic acid may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Etacrynic acid may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Etacrynic acid may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Etacrynic acid may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Valdecoxib.]
[C01AA06, lanatoside C, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lanatoside C.]
[N02CC05, almotriptan, Etacrynic acid may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH04, parecoxib, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Parecoxib.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Etacrynic acid.]
[N05BA10, ketazolam, Etacrynic acid may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AA06, kebuzone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Kebuzone.]
[C08CA09, lacidipine, Etacrynic acid may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lactitol.]
[N03AX09, lamotrigine, Etacrynic acid may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA03, cortisone, The risk or severity of hypokalemia can be increased when Cortisone is combined with Etacrynic acid.]
[N07BC04, lofexidine, Etacrynic acid may increase the excretion rate of Lofexidine which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB09, lonazolac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lonazolac.]
[M02AA31, loxoprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Loxoprofen.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Etacrynic acid.]
[C09AA03, lisinopril, Etacrynic acid may increase the excretion rate of Lisinopril which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium carbonate.]
[B05XA10, magnesium phosphate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium phosphate.]
[C08CA11, manidipine, Etacrynic acid may increase the hypotensive activities of Manidipine.]
[H02AB15, meprednisone, The risk or severity of hypokalemia can be increased when Meprednisone is combined with Etacrynic acid.]
[J01DH02, meropenem, Etacrynic acid may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Eplerenone is combined with Etacrynic acid.]
[N05AD03, metylperon, Etacrynic acid may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA07, cyclopenthiazide, Etacrynic acid may increase the hypotensive activities of Cyclopenthiazide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Etacrynic acid.]
[J05AF07, tenofovir disoproxil, Etacrynic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Etacrynic acid.]
[S01XA18, cyclosporine, The risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Etacrynic acid.]
[C09AA13, moexipril, The risk or severity of adverse effects can be increased when Moexipril is combined with Etacrynic acid.]
[M02AA02, mofebutazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mofebutazone.]
[M01AX22, morniflumate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Morniflumate.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Conivaptan is combined with Etacrynic acid.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Moxonidine.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Etacrynic acid.]
[M01AH05, etoricoxib, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etoricoxib.]
[L01AX04, dacarbazine, Etacrynic acid may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03CA01, dantrolene, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Dantrolene.]
[C02CC04, debrisoquin, Etacrynic acid may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Etacrynic acid.]
[M01AX01, nabumetone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nabumetone.]
[N07BB05, nalmefene, Etacrynic acid may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Potassium lactate.]
[J01AA01, demeclocycline, The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Etacrynic acid.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nebivolol.]
[S01GX04, nedocromil, Etacrynic acid may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, Etacrynic acid may increase the excretion rate of Nefazodone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Etacrynic acid.]
[L02BB02, nilutamide, Etacrynic acid may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Etacrynic acid.]
[M03AC11, cisatracurium, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Etacrynic acid.]
[R05DA06, normethadone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Etacrynic acid may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC03, olsalazine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Olsalazine.]
[N06AA01, desipramine, Etacrynic acid may increase the excretion rate of Desipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AA07, deslanoside, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Deslanoside.]
[H01BA02, desmopressin, Etacrynic acid may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XC02, desoximetasone, The risk or severity of hypokalemia can be increased when Desoximetasone is combined with Etacrynic acid.]
[V04CH02, indigo carmine, Etacrynic acid may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA03, desoxycorticosterone, The risk or severity of hypokalemia can be increased when Desoxycortone is combined with Etacrynic acid.]
[J01DH03, ertapenem, Etacrynic acid may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aliskiren.]
[M01AE12, oxaprozin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxaprozin.]
[S03BA01, dexamethasone, The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Etacrynic acid.]
[N06BA02, dextroamphetamine, Etacrynic acid may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AC01, dextromoramide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dextromoramide.]
[N07BC06, heroin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diamorphine.]
[P03AC04, permethrin, Etacrynic acid may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, Etacrynic acid may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Diazoxide.]
[R05DA08, pholcodine, Etacrynic acid may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA02, clodronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Diclofenamide.]
[S01BC03, diclofenac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diclofenac.]
[J05AD01, foscarnet, Etacrynic acid may decrease the excretion rate of Foscarnet which could result in a higher serum level.]
[A03AA07, dicyclomine, Etacrynic acid may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF03, zalcitabine, The excretion of Zalcitabine can be decreased when combined with Etacrynic acid.]
[J05AF02, didanosine, Etacrynic acid may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DG01, pinacidil, Etacrynic acid may increase the hypotensive activities of Pinacidil.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Etacrynic acid.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pipamperone.]
[R03CC07, pirbuterol, The risk or severity of hypokalemia can be increased when Pirbuterol is combined with Etacrynic acid.]
[C08CA03, isradipine, Etacrynic acid may increase the excretion rate of Isradipine which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XC04, diflucortolone, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Etacrynic acid.]
[N02BA11, diflunisal, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin.]
[C02DB01, dihydralazine, Etacrynic acid may increase the hypotensive activities of Dihydralazine.]
[N02AA03, hydromorphone, Etacrynic acid may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Etacrynic acid may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Atazanavir.]
[B01AC21, treprostinil, Etacrynic acid may increase the hypotensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, Etacrynic acid may increase the excretion rate of Potassium perchlorate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB04, pralidoxime, Etacrynic acid may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DB01, diltiazem, The risk or severity of adverse effects can be increased when Diltiazem is combined with Etacrynic acid.]
[V03AB09, dimercaprol, Etacrynic acid may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC08, procaterol, The risk or severity of hypokalemia can be increased when Procaterol is combined with Etacrynic acid.]
[M02AX03, dimethyl sulfoxide, Etacrynic acid may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Propyphenazone.]
[M01AB14, proglumetacin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Proglumetacin.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Etacrynic acid.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diphenoxylate.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Quinapril is combined with Etacrynic acid.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dipyridamole.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Etacrynic acid.]
[S01AX06, resorcinol, Etacrynic acid may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Etacrynic acid.]
[N05AX08, risperidone, The risk or severity of hypotension can be increased when Etacrynic acid is combined with Risperidone.]
[R06AE09, levocetirizine, Etacrynic acid may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB09, ropivacaine, Etacrynic acid may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Etacrynic acid.]
[G04BE08, tadalafil, Etacrynic acid may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC05, ketorolac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, Etacrynic acid may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, Etacrynic acid may increase the excretion rate of Ranolazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA06, salsalate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Etacrynic acid.]
[H05BA01, salmon calcitonin, Etacrynic acid may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, The risk or severity of hypokalemia can be increased when Dobutamine is combined with Etacrynic acid.]
[C01CA04, dopamine, Etacrynic acid may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA12, doxepin, Etacrynic acid may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sennosides.]
[J01AA02, doxycycline, Etacrynic acid may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sevoflurane.]
[A08AA10, sibutramine, Etacrynic acid may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AG05, sodium phosphate, Etacrynic acid may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sodium sulfate.]
[C09AA11, spirapril, Etacrynic acid may increase the hypotensive activities of Spirapril.]
[R03DA01, dyphylline, Etacrynic acid may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC01, sumatriptan, Etacrynic acid may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX07, edrophonium, Etacrynic acid may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, Etacrynic acid may increase the hypotensive activities of Talinolol.]
[H01AA01, corticotropin, The risk or severity of hypokalemia can be increased when Corticotropin is combined with Etacrynic acid.]
[J01CG02, tazobactam, The excretion of Tazobactam can be decreased when combined with Etacrynic acid.]
[L01AX03, temozolomide, Etacrynic acid may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tenoxicam.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Terazosin.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Enalapril is combined with Etacrynic acid.]
[M01AG02, tolfenamic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Etacrynic acid.]
[N06BA09, atomoxetine, Etacrynic acid may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX11, topiramate, The risk or severity of hypokalemia can be increased when Etacrynic acid is combined with Topiramate.]
[C03CA04, torsemide, The risk or severity of ototoxicity can be increased when Torasemide is combined with Etacrynic acid.]
[J01AA12, tigecycline, The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Etacrynic acid.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Etacrynic acid.]
[N05CC01, chloral hydrate, Etacrynic acid may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[H02CA01, trilostane, The risk or severity of hypokalemia can be increased when Trilostane is combined with Etacrynic acid.]
[C02CA06, urapidil, Etacrynic acid may increase the hypotensive activities of Urapidil.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Etacrynic acid.]
[N06AX16, venlafaxine, Etacrynic acid may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of hypokalemia can be increased when Epinephrine is combined with Etacrynic acid.]
[C09AA15, zofenopril, Etacrynic acid may increase the hypotensive activities of Zofenopril.]
[M01AB04, zomepirac, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Zomepirac.]
[N03AX15, zonisamide, Etacrynic acid may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Etacrynic acid.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Carboplatin.]
[C02AC02, guanfacine, Etacrynic acid may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Iloprost.]
[L03AX05, pidotimod, Etacrynic acid may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD04, estazolam, Etacrynic acid may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Etacrynic acid may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA03, estradiol, Etacrynic acid may increase the excretion rate of Estradiol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA57, estrogens, conjugated (USP), Etacrynic acid may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, Etacrynic acid may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08CA03, gadodiamide, Etacrynic acid may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amifostine.]
[C01BD05, ibutilide, Etacrynic acid may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC06, meloxicam, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ethylmorphine.]
[N01AX07, etomidate, Etacrynic acid may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Etacrynic acid.]
[P01AX07, trimetrexate, Etacrynic acid may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, Etacrynic acid may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB08, fluvoxamine, Etacrynic acid may increase the excretion rate of Fluvoxamine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE02, leuprolide, Etacrynic acid may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01CB01, gold sodium thiomalate, Etacrynic acid may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, Etacrynic acid may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA01, etidronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Etidronic acid.]
[V03AF02, dexrazoxane, Etacrynic acid may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA01, levocarnitine, Etacrynic acid may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA02, felodipine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.]
[M01AE04, fenoprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of hypokalemia can be increased when Fenoterol is combined with Etacrynic acid.]
[N02AB03, fentanyl, Etacrynic acid may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, The risk or severity of hypokalemia can be increased when Salbutamol is combined with Etacrynic acid.]
[L01BB06, clofarabine, Etacrynic acid may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07AX03, cevimeline, Etacrynic acid may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Etacrynic acid may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG04, floctafenine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Floctafenine.]
[J02AC01, fluconazole, Etacrynic acid may increase the excretion rate of Fluconazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AX01, flucytosine, Etacrynic acid may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA02, fludrocortisone, The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Etacrynic acid.]
[V03AB25, flumazenil, Etacrynic acid may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XB01, flumethasone, The risk or severity of hypokalemia can be increased when Flumethasone is combined with Etacrynic acid.]
[D07AC08, fluocinonide, The risk or severity of hypokalemia can be increased when Fluocinonide is combined with Etacrynic acid.]
[H02AB03, fluocortolone, The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Etacrynic acid.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Etacrynic acid.]
[L01BC09, floxuridine, Etacrynic acid may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD01, flurazepam, Etacrynic acid may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Flurbiprofen.]
[L02BB01, flutamide, Etacrynic acid may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Etacrynic acid may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Etacrynic acid may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA07, framycetin, The serum concentration of Framycetin can be increased when it is combined with Etacrynic acid.]
[L01BC03, tegafur, Etacrynic acid may increase the excretion rate of Tegafur which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AA01, alcuronium, The therapeutic efficacy of Alcuronium can be increased when used in combination with Etacrynic acid.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Etacrynic acid.]
[C03CA01, furosemide, Furosemide may increase the ototoxic activities of Etacrynic acid.]
[M05BA04, alendronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Alendronic acid.]
[N05CF04, eszopiclone, Etacrynic acid may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC02, gallamine, The therapeutic efficacy of Gallamine can be increased when used in combination with Etacrynic acid.]
[S01AD09, ganciclovir, Etacrynic acid may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Etacrynic acid.]
[C10AB04, gemfibrozil, Etacrynic acid may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XA03, telavancin, Etacrynic acid may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Etacrynic acid.]
[N01AH02, alfentanil, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Alfentanil.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Etacrynic acid.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Etacrynic acid.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Etacrynic acid.]
[N05CM18, dexmedetomidine, Etacrynic acid may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Glycerin.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Etacrynic acid.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Etacrynic acid is combined with Dofetilide.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Etacrynic acid.]
[L01EX02, sorafenib, Etacrynic acid may increase the excretion rate of Sorafenib which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Etacrynic acid.]
[M01CB04, aurothioglucose, Etacrynic acid may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Etacrynic acid may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA12, fluindione, The protein binding of Fluindione can be decreased when combined with Etacrynic acid.]
[C09AA09, fosinopril, Etacrynic acid may increase the excretion rate of Fosinopril which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EX01, guanethidine, Etacrynic acid may increase the excretion rate of Guanethidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE03, goserelin, Etacrynic acid may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD01, haloperidol, Etacrynic acid may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Halothane.]
[N05AH04, quetiapine, Etacrynic acid may increase the excretion rate of Quetiapine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX13, idebenone, Etacrynic acid may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Etacrynic acid.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Allopurinol.]
[C09CA01, losartan, The risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium citrate.]
[A12CC03, magnesium gluconate, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium gluconate.]
[G03DC01, allylestrenol, Etacrynic acid may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Etacrynic acid.]
[C01CE02, milrinone, Etacrynic acid may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sodium fluorophosphate.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Etacrynic acid.]
[R03CC05, hexoprenaline, The risk or severity of hypokalemia can be increased when Hexoprenaline is combined with Etacrynic acid.]
[C08CA10, nilvadipine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nilvadipine.]
[M02AA26, nimesulide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nimesulide.]
[C09AA04, perindopril, Etacrynic acid may increase the excretion rate of Perindopril which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DB02, hydralazine, Etacrynic acid may increase the excretion rate of Hydralazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Etacrynic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Etacrynic acid.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Etacrynic acid.]
[B05XA17, potassium acetate, Etacrynic acid may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Etacrynic acid may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Etacrynic acid may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA07, hetastarch, Etacrynic acid may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC06, rilmenidine, Etacrynic acid may increase the hypotensive activities of Rilmenidine.]
[M05BA07, risedronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Risedronic acid.]
[R02AX02, ibuprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ibuprofen.]
[B05XA08, sodium acetate, Etacrynic acid may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sodium tartrate.]
[L01AA06, ifosfamide, Etacrynic acid may increase the excretion rate of Ifosfamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AH03, sufentanil, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, Etacrynic acid may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Paclitaxel.]
[R01AD07, tixocortol, Etacrynic acid may increase the excretion rate of Tixocortol which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Etacrynic acid.]
[L01CE01, topotecan, Etacrynic acid may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, Etacrynic acid may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indomethacin.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Indoramin.]
[A11HA07, inositol, Etacrynic acid may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, Etacrynic acid may increase the excretion rate of Milnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA02, cyclopentamine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cyclopentamine.]
[S01XA28, varenicline, Etacrynic acid may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Etacrynic acid.]
[N05BA12, alprazolam, Etacrynic acid may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Etacrynic acid may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Etacrynic acid.]
[C07AA01, alprenolol, Etacrynic acid may increase the hypotensive activities of Alprenolol.]
[V03AB01, ipecac, Etacrynic acid may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF04, stavudine, The excretion of Stavudine can be decreased when combined with Etacrynic acid.]
[G04BE01, alprostadil, The excretion of Alprostadil can be decreased when combined with Etacrynic acid.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Etacrynic acid.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Etacrynic acid.]
[R03CC06, isoetharine, The risk or severity of hypokalemia can be increased when Isoetharine is combined with Etacrynic acid.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Etacrynic acid.]
[J04AC01, isoniazid, Etacrynic acid may increase the excretion rate of Isoniazid which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AX05, inosine pranobex, Etacrynic acid may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB01, isoproterenol, The risk or severity of hypokalemia can be increased when Isoprenaline is combined with Etacrynic acid.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Etacrynic acid.]
[C01DA14, isosorbide mononitrate, Etacrynic acid may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Etacrynic acid.]
[D10BA01, isotretinoin, Etacrynic acid may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isoxsuprine.]
[S01AA24, kanamycin, The serum concentration of Kanamycin can be increased when it is combined with Etacrynic acid.]
[N01AX03, ketamine, Etacrynic acid may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KD01, ketanserin, Etacrynic acid may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, Etacrynic acid may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Etacrynic acid.]
[M02AA10, ketoprofen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketoprofen.]
[C01CA22, arbutamine, The risk or severity of hypokalemia can be increased when Arbutamine is combined with Etacrynic acid.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Rotigotine.]
[D10AX03, azelaic acid, Etacrynic acid may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE11, tiaprofenic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tiaprofenic acid.]
[C07AG01, labetalol, Etacrynic acid may increase the excretion rate of Labetalol which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BB01, amantadine, Etacrynic acid may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA05, deserpidine, Etacrynic acid may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lubiprostone.]
[M01AG01, mefenamic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Etacrynic acid may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA09, fluticasone furoate, The risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Etacrynic acid is combined with Levodopa.]
[J01FF02, lincomycin, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Lincomycin.]
[S01AA21, amikacin, The serum concentration of Amikacin can be increased when it is combined with Etacrynic acid.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Etacrynic acid.]
[N05BA06, lorazepam, Etacrynic acid may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01AA04, lymecycline, The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Etacrynic acid.]
[B05XA11, magnesium chloride, Etacrynic acid may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Etacrynic acid may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Etacrynic acid.]
[N06AA21, maprotiline, Etacrynic acid may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Mecamylamine.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meclofenamic acid.]
[C01AA08, medigoxin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metildigoxin.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Frangula purshiana bark.]
[N06DX01, memantine, Etacrynic acid may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, Etacrynic acid may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Etacrynic acid.]
[N01BB03, mepivacaine, Etacrynic acid may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Etacrynic acid may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BC01, mersalyl, Etacrynic acid may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Etacrynic acid may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid.]
[J01AA05, methacycline, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Metacycline.]
[N07BC02, methadone, Etacrynic acid may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA03, methamphetamine, Etacrynic acid may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF05, lamivudine, Etacrynic acid may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Etacrynic acid.]
[H03BB02, methimazole, Etacrynic acid may increase the excretion rate of Methimazole which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BA04, pemetrexed, Etacrynic acid may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Etacrynic acid.]
[A11HA02, pyridoxine, Etacrynic acid may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Etacrynic acid is combined with Ziconotide.]
[L04AX03, methotrexate, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methotrexate.]
[D05BA02, methoxsalen, Etacrynic acid may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Methylcellulose.]
[C02AB01, methyldopa, Etacrynic acid may increase the excretion rate of Methyldopa which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Etacrynic acid.]
[H02AB04, methylprednisolone, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Etacrynic acid.]
[G03EK01, methyltestosterone, Etacrynic acid may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA01, metoclopramide, Etacrynic acid may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, Etacrynic acid may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Etacrynic acid may increase the excretion rate of Metoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CD01, metyrapone, Etacrynic acid may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB03, aminopyrine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Aminophenazone.]
[N05CD08, midazolam, Etacrynic acid may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Etacrynic acid.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Mineral oil.]
[J05AH01, zanamivir, Etacrynic acid may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid.]
[J01AA08, minocycline, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Minocycline.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Etacrynic acid.]
[L03AC01, aldesleukin, Etacrynic acid may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amiodarone.]
[N06AA09, amitriptyline, Etacrynic acid may increase the excretion rate of Amitriptyline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA01, morphine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Morphine.]
[A04AA05, palonosetron, Etacrynic acid may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Etacrynic acid may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BA01, ammonium chloride, Etacrynic acid may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA06, mycophenolic acid, Etacrynic acid may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC03, vecuronium, The therapeutic efficacy of Vecuronium can be increased when used in combination with Etacrynic acid.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Etacrynic acid.]
[C07AA12, nadolol, Etacrynic acid may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA04, amoxicillin, Etacrynic acid may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Etacrynic acid.]
[N02AF02, nalbuphine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, Etacrynic acid may increase the excretion rate of Naloxone which could result in a lower serum level and potentially a reduction in efficacy.]
[N07BB04, naltrexone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naltrexone.]
[N06BA01, amphetamine, Etacrynic acid may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naproxen.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Etacrynic acid.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Etacrynic acid is combined with Duloxetine.]
[N04BX01, tolcapone, Etacrynic acid may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Neomycin.]
[N01AH06, remifentanil, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Remifentanil.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Etacrynic acid.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Levosimendan.]
[B01AC17, tirofiban, Etacrynic acid may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Etacrynic acid.]
[S01AA19, ampicillin, Etacrynic acid may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Etacrynic acid may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA23, netilmicin, The serum concentration of Netilmicin can be increased when it is combined with Etacrynic acid.]
[N06AX23, desvenlafaxine, Etacrynic acid may increase the excretion rate of Desvenlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Telmisartan.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Etacrynic acid.]
[C01CE01, inamrinone, Etacrynic acid may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Etacrynic acid.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Etacrynic acid.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nicotine.]
[C08CA05, nifedipine, Etacrynic acid may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA17, niflumic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of adverse effects can be increased when Nimodipine is combined with Etacrynic acid.]
[C08CA07, nisoldipine, Etacrynic acid may increase the excretion rate of Nisoldipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA08, nitrendipine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nitrendipine.]
[R07AX01, nitric oxide, Etacrynic acid may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Etacrynic acid may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF03, zaleplon, Etacrynic acid may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Etacrynic acid may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, Etacrynic acid may increase the excretion rate of Nitroprusside which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA03, norepinephrine, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Etacrynic acid.]
[C02KX01, bosentan, Etacrynic acid may increase the hypotensive activities of Bosentan.]
[N02AA02, opium, Etacrynic acid may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB03, metaproterenol, The risk or severity of hypokalemia can be increased when Orciprenaline is combined with Etacrynic acid.]
[G04CA02, tamsulosin, Etacrynic acid may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AC01, ouabain, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ouabain.]
[M05BA08, zoledronic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Zoledronic acid.]
[J01CF04, oxacillin, Etacrynic acid may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA04, oxazepam, Etacrynic acid may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxycodone.]
[N02AA11, oxymorphone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxymorphone.]
[S01BC02, oxyphenbutazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxyphenbutazone.]
[S01AA04, oxytetracycline, The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Etacrynic acid.]
[V04CH30, 4-aminohippuric acid, The excretion of Aminohippuric acid can be decreased when combined with Etacrynic acid.]
[J04AA01, aminosalicylic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aminosalicylic acid.]
[N02AX06, tapentadol, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tapentadol.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be increased when used in combination with Etacrynic acid.]
[J04AB30, capreomycin, The serum concentration of Capreomycin can be increased when it is combined with Etacrynic acid.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of hypokalemia can be increased when Paramethasone is combined with Etacrynic acid.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Etacrynic acid.]
[A07AA06, paromomycin, The serum concentration of Paromomycin can be increased when it is combined with Etacrynic acid.]
[G04BD11, fesoterodine, Etacrynic acid may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, Etacrynic acid may increase the excretion rate of Penbutolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CE09, penicillin G procaine, Etacrynic acid may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AD01, pentazocine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Etacrynic acid.]
[L01XX08, pentostatin, Etacrynic acid may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Etacrynic acid may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AD02, phenazocine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Phenazopyridine.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Etacrynic acid.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Etacrynic acid.]
[B01AA02, phenindione, The protein binding of Phenindione can be decreased when combined with Etacrynic acid.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Etacrynic acid.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The protein binding of Phenprocoumon can be decreased when combined with Etacrynic acid.]
[V03AB36, phentolamine, Etacrynic acid may increase the excretion rate of Phentolamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA01, phenylbutazone, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenylbutazone.]
[R01BA01, phenylpropanolamine, The risk or severity of hypokalemia can be increased when Phenylpropanolamine is combined with Etacrynic acid.]
[S01AE05, levofloxacin, Etacrynic acid may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B02BA01, vitamin K1, Etacrynic acid may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Etacrynic acid.]
[C08CX01, mibefradil, Etacrynic acid may increase the hypotensive activities of Mibefradil.]
[C07AA03, pindolol, Etacrynic acid may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA12, piperacillin, Etacrynic acid may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX03, piracetam, Etacrynic acid may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Eprosartan is combined with Etacrynic acid.]
[N02AC03, pirinitramide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Piroxicam.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefditoren.]
[J01MA11, grepafloxacin, The excretion of Grepafloxacin can be decreased when combined with Etacrynic acid.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Irbesartan.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Etacrynic acid.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Polyethylene glycol.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Polymyxin B.]
[C03AA05, polythiazide, Etacrynic acid may increase the hypotensive activities of Polythiazide.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Etacrynic acid.]
[B05XA01, potassium chloride, Etacrynic acid may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Etacrynic acid.]
[C07AB01, practolol, Etacrynic acid may increase the hypotensive activities of Practolol.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Etacrynic acid.]
[S03BA02, prednisolone, The risk or severity of hypokalemia can be increased when Prednisolone is combined with Etacrynic acid.]
[H02AB07, prednisone, The risk or severity of hypokalemia can be increased when Prednisone is combined with Etacrynic acid.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Etacrynic acid.]
[M04AB01, probenecid, The risk or severity of adverse effects can be increased when Probenecid is combined with Etacrynic acid.]
[C01BA02, procainamide, Etacrynic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, Procaine may increase the orthostatic hypotensive activities of Etacrynic acid.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Etacrynic acid.]
[C10AB05, fenofibrate, Etacrynic acid may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD02, promethazine, Etacrynic acid may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB05, propantheline, Etacrynic acid may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Etacrynic acid.]
[N02AC04, propoxyphene, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dextropropoxyphene.]
[C07AA05, propranolol, Etacrynic acid may increase the excretion rate of Propranolol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AB01, proscillaridin, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Proscillaridin.]
[N02CC04, rizatriptan, Etacrynic acid may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, Etacrynic acid may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX12, aripiprazole, Aripiprazole may increase the hypotensive activities of Etacrynic acid.]
[N07XX07, dalfampridine, Etacrynic acid may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CC01, pyrantel, The therapeutic efficacy of Pyrantel can be increased when used in combination with Etacrynic acid.]
[J04AK01, pyrazinamide, Etacrynic acid may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA01, quinidine, Etacrynic acid may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Etacrynic acid.]
[A02BA02, ranitidine, Etacrynic acid may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, Etacrynic acid may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, Etacrynic acid may increase the excretion rate of Reserpine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP01, ribavirin, Etacrynic acid may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CA01, ritodrine, The risk or severity of hypokalemia can be increased when Ritodrine is combined with Etacrynic acid.]
[J01AA09, rolitetracycline, The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Rolitetracycline.]
[N02BA05, salicylamide, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salicylic acid.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Etacrynic acid.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Etacrynic acid.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Obinutuzumab.]
[J01GB08, sisomicin, The serum concentration of Sisomicin can be increased when it is combined with Etacrynic acid.]
[A12CD01, sodium fluoride, Etacrynic acid may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sorbitol.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Etacrynic acid.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Etacrynic acid.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Etacrynic acid.]
